Misdiagnosed as Ankylosing Spondylitis: An Unusual Case of Acute Promyelocytic Leukemia with Myeloid Sarcoma

Document Type : Case Report

Authors

1 Hematologist-Oncologist, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

10.22038/psj.2025.86217.1461

Abstract

Introduction:
Acute promyelocytic leukemia (APL) accounts for 7-8% of adult acute myeloid leukemia cases. Extramedullary manifestations in APL are rare at initial diagnosis and exhibit unique biological characteristics.
 Case presentation:
 This study aimed to report a unique case of a 31-year-old male who initially presented with lower back pain and was misdiagnosed with Ankylosing Spondylitis. Subsequent development of cervical lymphadenopathy led to further investigation, revealing myeloid sarcoma and APL with Promyelocytic Leukemia/Retinoic Acid Receptor Alpha translocation. The patient underwent standard all-trans-retinoic acid therapy, followed by consolidation chemotherapy. Despite a relapse, the patient achieved complete remission after treatment with arsenic trioxide and a bone marrow transplant, which is uncommon for APL patients.
 Conclusion:
This case underscores the importance of considering hematologic malignancies in patients with atypical presentations and highlights the role of genetic testing in confirming diagnoses. The successful use of a bone marrow transplant in this case suggests potential benefits for selected APL patients with extramedullary involvement and relapse.

Keywords

Main Subjects

References

  1. Cingam SR, Koshy NV. Cancer, Acute Promyelocytic Leukemia. StatPearls. Treasure Island (FL)2020.
  2. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5(4):e304.
  3. Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447-53.
  4. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, et al. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009;89(4):489-96.
  5. Pacilli L, Lo Coco F, Ramadan SM, Giannì L, Pingi A, Remotti D, et al. Promyelocytic sarcoma of the spine: a case report and review of the literature. Adv Hematol. 2010; 2010:137608.
  6. Ganzel C, Douer D. Extramedullary disease in APL: A real phenomenon to contend with or not? Best Practice & Research Clinical Haematology. 2014;27(1):63-8.
  7. Zou XL, Zeng K, Xie LP, Wang L, Chen M, Liu T, et al. Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse. Acta Haematol. 2013;130(4):223-9.
  8. Ko BS, Tang JL, Chen YC, Yao M, Wang CH, Shen MC, et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia--the occurrence of retinoic acid syndrome is a risk factor. Leukemia. 1999;13(9):1406-8.
  9. Disel U, Yavuz S, Paydas S, Sahin B, Zeren H. Extramedullary relapse in the pleura in acute promyelocytic leukemia. Leuk Lymphoma. 2003; 44(1):189-91.
  10. Tirado CA, Chen W, Valdez F, Karandikar N, Arbini A, Acevedo I, et al. unusual presentation of myeloid sarcoma in a case of acute promyelocytic leukemia with a cryptic PML-RARA rearrangement involving multiple sites including the atrium. Cancer Genet Cytogenet. 2010; 200(1): 47-53.
  11. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785-93.
  12. Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia. 2015; 29(5):1084-91.
  13. Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013; 121(16): 3095-102.
  14. Yanada M, Yano S, Kanamori H, Gotoh M, Emi N, Watakabe K, et al. Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. Leuk Lymphoma. 2017; 58(5):1061-7.
  15. Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB, et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant. 2014; 20(7):1021-5.
  16. Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2. Bone Marrow Transplant. 2016; 51(9):1180-3.
  17. Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, et al. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood. 2018;132(13):1452-4.
  18. Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, et al. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Ann Hematol. 2018; 97(10):1797-802.
  19. Costa A, Gurnari C, Scalzulli E, Cicconi L, Guarnera L, Carmosino I, et al. Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia. Cancers. 2024; 16(18):3214.
  20. Fouzia NA, Sharma V, Ganesan S, Palani HK, Balasundaram N, David S, et al. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Br J Haematol. 2021;192(2):292-9.
  21. Sanz J, Labopin M, Sanz MA, Aljurf M, Sousa AB, Craddock C, et al. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplant. 2021; 56(6): 1272-80.
Journal of Patient Safety & Quality Improvement
Volume 13, Issue 2
April 2025
Pages 147-150

Files

Share

How to cite

Statistics